Mayne Pharma has opened a new 126,000-square-foot oral solid-dose manufacturing facility to meet demand driven by new product launches – and new revenue stream from its CDMO business.
Pills embedded with sensor technology that verifies a patient has taken their medication can improve adherence and provide data on adverse effects, says Proteus Digital Health’s Nik Leist.
Almac Group has expanded its commercial packaging capabilities to meet a “significant increase” in demand for complex kit assembly as biopharma brings more advanced sterile and biological products to the market, says CDMO.
The US FDA has issued a recall of non-expired products marketed as sterile made by Coastal Meds after an investigation of the outsourcing facility found poor sterile production practices.
Nanoparticle delivery technology that transports compounds to the bloodstream and cells can increase bioavailability and reduce adverse effects of cannabinoids and bioactive compounds, says NanoSphere Health Sciences.
Porton Biopharma will look to develop GMP manufacturing capabilities for Clostridia bacteria as part of a UK collaboration developing aimed at developing microbiome targeted therapeutics.
‘Splinter-like’ nanostructures have been developed by researchers in the US to deliver biomolecules straight into patient cells for immune-oncology and gene therapies.
A new method to predict the physical stability of drug candidates is attracting interest from pharmaceutical companies who could use the technology to de-risk early development.
